SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maul Coin

Maul Coin is generating buzz as a community-driven project aiming to replicate the massive growth of previous viral memecoins through active social media raiding and a transparent developer-led approach. While the community is currently focused on overcoming technical hurdles like securing official charts and listings, members are heavily incentivized by the potential for 1000x gains and a movement-based ethos that rejects typical 'pump and dump' behavior.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash is attracting significant community attention as traders debate its potential for a breakout, with many highlighting the upcoming Layla upgrade in May 2026 as a pivotal catalyst for increased utility and quantum resistance. While bulls point to resilient price action and the network's low-fee, peer-to-peer focus, ongoing discussions remain polarized between those expecting a major decoupling from Bitcoin and critics dismissing the asset due to historical performance concerns.

Oscar Health, Inc. is a healthcare insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is capturing significant investor attention as markets weigh the company's ambitious 2026 profitability guidance against its recent quarterly earnings miss. While the community remains deeply divided between those betting on long-term growth through AI-driven operational efficiency and skeptics concerned about medical loss ratios, retail traders are closely tracking the stock's volatility ahead of potential structural pivots in the healthcare sector.

Nucor Corp. engages in the manufacture of steel products, and ferrous and non-ferrous materials. It operates through the following segments: Steel Mills, Steel Products, and Raw Materials. The Steel Mills segment consists of producing sheet, plate, structural, and bar steel. The Steel Products segment includes steel joists and joist girders, deck, fabricated concrete reinforcing, cold finished, fasteners, metal building systems, grating, tubular, piling products businesses, and wire mesh. The Raw Materials segment consists of direct reduced iron, and ferrous and nonferrous metals. The company was founded by Ransom E. Olds in 1905 and is headquartered in Charlotte, NC.

Nucor Corp.

Nucor is trending as investors react to the anticipated formalization of 25% tariffs on global steel and aluminum imports. The community is actively discussing how these protective measures may bolster domestic manufacturing demand and pricing power, with some participants expressing caution regarding potential inflationary impacts and global trade volatility.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BCRX is trending due to surging after-hours volume and unconfirmed speculation regarding a potential buyout, which has intensified community discussion about its valuation and long-term pipeline potential. Investors are closely monitoring unusual block trades and technical price action, viewing these signals as potential precursors to an M&A event despite historical skepticism regarding the company's independence.

SiriusXM Holdings, Inc. engages in the provision of audio entertainment. It operates through the Sirius XM and Pandora and Off-Platform segments. The Sirius XM segment features a wide range of content, including, music, sports, entertainment, comedy, talk and news channels, podcasts and infotainment services, all available in the United States on a subscription fee basis. The Pandora and Off-Platform segment generates a majority of its revenues from third parties advertising on the Pandora ad-supported service and other platforms. The company was founded on May 17, 1990, and is headquartered in New York, NY.

Sirius XM Holdings Inc.

Sirius XM Holdings Inc

Sirius XM Holdings is attracting intense investor attention as Berkshire Hathaway continues to aggressively increase its stake, signaling strong institutional confidence despite recent downward price pressure. The community is actively debating the company's valuation, dividend stability, and the potential impact of high short interest amid ongoing speculation regarding future content strategies and M&A activity.

Invesco DB US Dollar Index Bullish Fund - Common units of beneficial interest

Invesco DB US Dollar Index Bullish Fund

The Invesco DB US Dollar Index Bullish Fund is trending as market participants weigh conflicting signals between safe-haven demand amid rising Middle East geopolitical tensions and concerns over long-term fiscal deficits. Traders are actively debating the dollar's strength relative to precious metals and foreign currencies as they monitor key labor data and shifting central bank interest rate policies.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group is trending due to heightened investor focus on the upcoming PDUFA decision date for RP1, with market participants debating whether the resubmission successfully addresses previous FDA concerns or if a second Complete Response Letter is likely. The community remains deeply divided, with some traders citing unusual options volume and potential short-covering as bullish indicators, while skeptics warn of significant downside risk if the company fails to secure accelerated approval.

What Is Tezos (XTZ)?   Tezos is a high-performing blockchain and open-source platform for assets and applications, with a strong focus on code security, on-chain governance, and decentralization. Tezos 2.0, the upcoming step in the evolution of Tezos, aims to improve scalability (via layer 2s), composability, and to implement support to mainstream programming languages (like Javascript, Typescript, Python, and many others).   Initially built with formal verification in mind, the Tezos protocol enables builders to avoid bugs when developing smart contracts, making it particularly suited to applications that require a high degree of security and certainty.   Tezos’ LPoS (Liquid Proof-of-Stake) consensus mechanism enables any stakeholder to take part, directly or by delegation, in the consensus process, and to be rewarded for securing the network. Rather uniquely, Tezos’ on-chain governance system also enables stakeholders to create and vote on protocol upgrade proposals. This pioneering system allows the protocol to self-amend and upgrade itself without leading to a split (or fork) in the blockchain, empowering the community without slowing down innovation.   First proposed in 2014 and launched in 2018, the Tezos Mainnet has a proven track record of running uninterrupted ever since, having earned a strong reputation for technical excellence and a supportive community.    Who Are the Founders of Tezos? Tezos was conceived by Arthur and Kathleen Breitman in a 2014 white paper under the pseudonym L.M. Goodman in a nod to Satoshi Nakamoto, referencing a journalist who had misidentified the creator of Bitcoin.   In a previous paper, the Breitmans had argued that Bitcoin's biggest shortcomings were the lack of a governance process that invited contributions from its community of users, cost and centralization issues raised by its proof-of-work system, the limited expressiveness of its programming language which didn’t allow for smart contracts, and security

Tezos

Tezos is currently generating intense debate among retail traders, with many participants expressing extreme bearish sentiment and anticipation of further downward price movement. The community remains deeply divided, with vocal skeptics labeling the project a "ghost chain" while contrarian traders continue to monitor support levels in search of potential re-entry points.

Wells Fargo & Co. is a diversified and community-based financial services company, which engages in the provision of banking, insurance, investments, mortgage, and consumer and commercial finance products and services. It operates through the following segments: Consumer Banking and Lending, Commercial Banking, Corporate and Investment Banking, and Wealth and Investment Management. The Consumer Banking and Lending segment offers consumer and small business banking, home lending, credit cards, auto, and personal lending. The Commercial Banking segment provides banking and credit products across industry sectors and municipalities, secured lending and lease products, and treasury management. The Corporate and Investment Banking segment is composed of corporate banking, investment banking, treasury management, commercial real estate lending and servicing, and equity and fixed income solutions, as well as sales, trading, and research capabilities. The Wealth and Investment Management segment refers to personalized wealth management, brokerage, financial planning, lending, private banking, trust, and fiduciary products and services. The company was founded by Henry Wells and William G. Fargo on March 18, 1852 and is headquartered in San Francisco, CA.

Wells Fargo & Co.

Wells Fargo is trending as investors digest the bank's latest earnings report and its ongoing progress in streamlining operations following the lifting of long-standing regulatory asset caps. The community is actively discussing the stock's growth potential versus valuation concerns, alongside a notable $85 million settlement related to past internal control and hiring practices.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Hennion & Walsh Asset Management Inc. Invests $1.70 Million in Taysha Gene Therapies, Inc. $TSHA

Hennion & Walsh Asset Management Inc. bought a new position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 308,457 shares of the com...

SG Americas Securities LLC Acquires 748,525 Shares of Taysha Gene Therapies, Inc. $TSHA

SG Americas Securities LLC boosted its holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 2,271.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 781,474 shares of the company's stock a...

Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 8.5% - Should You Buy?

Taysha Gene Therapies (NASDAQ:TSHA) Trading 8.5% Higher - Here's Why...

Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.9%  - Time to Sell?

Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.9% - Should You Sell...

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of "Moderate Buy" from Brokerages

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) have been given a consensus rating of "Moderate Buy" by the twelve ratings firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, ten have given a buy...

Taysha Gene Therapies (NASDAQ:TSHA) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen raised Taysha Gene Therapies from a "sell" rating to a "hold" rating in a research report on Saturday...

Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $12.00 at Needham & Company LLC

Needham & Company LLC increased their target price on shares of Taysha Gene Therapies from $10.00 to $12.00 and gave the stock a "buy" rating in a research report on Thursday...

Chardan Capital Reaffirms "Buy" Rating for Taysha Gene Therapies (NASDAQ:TSHA)

Chardan Capital reaffirmed a "buy" rating and set a $12.00 price target on shares of Taysha Gene Therapies in a research note on Thursday...

Taysha Gene Therapies Q4 Earnings Call Highlights

Taysha Gene Therapies (NASDAQ:TSHA) highlighted clinical, regulatory, and commercial progress for its lead Rett syndrome gene therapy program while also reporting higher operating expenses and a...

Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up After Better-Than-Expected Earnings

Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up After Earnings Beat...

Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.

Taysha Gene Therapies Inc

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

Current Price	$4.37
Prev Close	$4.31
Open	$4.18
Dividend Yield	0.00%
50-Day Moving Average	$4.56
Beta	1.66
Avg. Volume	3.13M
PE Ratio	-12.12

52-Week High	$6.02
52-Week Low	$1.05
Market Capitalization	$1.26B
EPS (Annual)	-$0.3409
Price to Book	5.04
Revenue Per Employee	$98,717.17

TSHA
Taysha Gene Therapies Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TSHA News

TSHATaysha Gene Therapies Inc